Electrophysiological characterization of iCell2 hiPSC derived cardiomyocytes: the new generation of CDI hiPSC-CMs

@inproceedings{Taylor2016ElectrophysiologicalCO,
  title={Electrophysiological characterization of iCell2 hiPSC derived cardiomyocytes: the new generation of CDI hiPSC-CMs},
  author={Alison Joan Taylor and V{\'i}ctor Orcajada Zamora and Maria P. Hortigon-Vinagre and Alastair J. Allan and Francis L. Burton and Blake D. Anson and Margaret Anne Craig and Godfrey L. Smith},
  year={2016}
}
Abstract Most of the efforts in cardiac safety pharmacology are orientated towards the improvement of early stage drug screening. In this regard, the creation of in vitro human ventricular electrophysiology has been accelerated by the commercial availability hiPSC-CMs. Many studies have validated iCell cardiomycytes (Cellular Dynamics Inc.) as a robust model to carry out predictive cardiotoxicity, but the requirement of at least 10 days in vitro (DIV), increases the handling and associated… CONTINUE READING
BETA